Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion

The Food and Drug Administration issued guidance for evaluating the cardiovascular risk of new diabetes mellitus drugs in 2008. Accumulating evidence from several completed trials conducted within this framework raises questions as to whether requiring safety outcome studies for all new diabetes mel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur Heart J Cardiovasc Pharmacother
Autores principales: Zannad, Faiez, Stough, Wendy Gattis, Lipicky, Raymond J., Tamargo, Juan, Bakris, George L., Borer, Jeffrey S., Alonso García, Maria de los Angeles, Hadjadj, Samy, Koenig, Wolfgang, Kupfer, Stuart, McCullough, Peter A., Mosenzon, Ofri, Pocock, Stuart, Scheen, André J., Sourij, Harald, Van der Schueren, Bart, Stahre, Christina, White, William B., Calvo, Gonzalo
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2016
Materias:
Reviews
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907355/
https://ncbi.nlm.nih.gov/pubmed/27418973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ehjcvp/pvw007
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares